Noosa

Noosa Bio is an early-stage biotechnology company focused on the discovery and development of novel molecular glue degraders to treat hematologic malignancies and other cancers. Founded by pioneers in the field of targeted protein degradation, the company leverages a proprietary platform to identify small molecules that induce the degradation of previously undruggable disease-causing proteins. By harnessing the body's natural protein disposal system, Noosa Bio aims to create highly specific and potent therapies for patients with limited treatment options. The company operates primarily in the stealth or early-venture phase, backed by leading life science investors and academic expertise from the Dana-Farber Cancer Institute.